The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women

Bone

Volumn 46, Issue 3, 2010, Pages 592-597

  Naylor, K E ^a   Clowes, J A ^b   Finigan, J ^a   Paggiosi, M A ^a   Peel, N F A ^c   Eastell, R ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MAYO CLINIC   (United States)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bone density; Bone markers; Osteopenic; Postmenopausal; Raloxifene

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCIUM; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; RALOXIFENE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPENIA; OUTCOME ASSESSMENT; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BONE DISEASES, METABOLIC; BONE REMODELING; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; TREATMENT OUTCOME;

EID: 77649187377     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.10.043     Document Type: Article

References (34)

1. Gennari L., Merlotti D., Valleggi F., et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs. Aging. 2007, 24(5):361-379.
2. Morello K.C., Wurz G.T., DeGregorio M.W. SERMs: current status and future trends. Crit. Rev. Oncol. Hematol. 2002, 43(1):63-76.
3. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337(23):1641-1647.
4. Lufkin E.G., Whitaker M.D., Nickelsen T., et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J. Bone Miner. Res. 1998, 13(11):1747-1754.
5. Meunier P.J., Vignot E., Garnero P., et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos. Int. 1999, 10(4):330-336.
6. Jolly E.E., Bjarnason N.H., Neven P., et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003, 10(4):337-344.
7. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
8. Johnston C.C., Bjarnason N.H., Cohen F.J., et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch. Intern. Med. 2000, 160(22):3444-3450.
9. Reid I.R., Eastell R., Fogelman I., et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch. Intern. Med. 2004, 164(8):871-879.
10. Prestwood K.M., Gunness M., Muchmore D.B., et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J. Clin. Endocrinol. Metab. 2000, 85(6):2197-2202.
11. Ott S.M., Oleksik A., Lu Y., et al. Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J. Bone Miner. Res. 2002, 17(2):341-348.
12. Weinstein R.S., Parfitt A.M., Marcus R., et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos. Int. 2003, 14(10):814-822.
13. Delmas P.D., Ensrud K.E., Adachi J.D., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 2002, 87(8):3609-3617.
14. Siris E.S., Harris S.T., Eastell R., et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J. Bone Miner. Res. 2005, 20(9):1514-1524.
15. Bjarnason N.H., Sarkar S., Duong T., et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos. Int. 2001, 12(11):922-930.
16. Greenspan S.L., Emkey R.D., Bone H.G., et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2002, 137(11):875-883.
17. Sornay-Rendu E., Garnero P., Munoz F., et al. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone 2003, 33(1):159-166.
18. Lindsay R., Hart D.M., MacLean A., et al. Bone response to termination of oestrogen treatment. Lancet 1978, 1(8078):1325-1327.
19. Wasnich R.D., Bagger Y.Z., Hosking D.J., et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004, 11(6 Pt 1):622-630.
20. Tonino R.P., Meunier P.J., Emkey R., et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J. Clin. Endocrinol. Metab. 2000, 85(9):3109-3115.
21. Ensrud K.E., Barrett-Connor E.L., Schwartz A., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J. Bone Miner. Res. 2004, 19(8):1259-1269.
22. Stock J.L., Bell N.H., Chesnut C.H., et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am. J. Med. 1997, 103(4):291-297.
23. Greenspan S.L., Resnick N.M., Parker R.A. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003, 289(19):2525-2533.
24. Ravn P., Weiss S.R., Rodriguez-Portales J.A., et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J. Clin. Endocrinol. Metab. 2000, 85(4):1492-1497.
25. Ravn P., Bidstrup M., Wasnich R.D., et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann. Intern. Med. 1999, 131(12):935-942.
26. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
27. Michalska D., Stepan J.J., Basson B.R., et al. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2006, 91(3):870-877.
28. Curtis J.R., Westfall A.O., Cheng H., et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos. Int. 2008, 19(11):1613-1620.
29. Neele S.J., Evertz R., De Valk-De R.G., et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002, 30(4):599-603.
30. Clowes J.A., Peel N.F., Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2004, 89(3):1117-1123.
31. Clowes J.A., Peel N.F.A., Blumsohn A., et al. Can multiple measurements or pooled measurements reduce within-subject variability1. J. Bone Miner. Res. 2004, 19(Suppl 1):M136.
32. Hanson D.A., Weis M.A.E., Bollen A.M., et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen crosslinked N-telopeptides in urine. J. Bone Miner. Res. 1992, 7:1251-1258.
33. Glover S.J., Garnero P., Naylor K., et al. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008, 42(4):623-630.
34. Cranney A., Tugwell P., Zytaruk N., et al. Meta-analyses of therapies for postmenopausal osteoporosis: IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr. Rev. 2002, 23(4):524-528.